Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026

Related news

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update

KZRKezar Life Sciences2020-05-28 20:01 EST

Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference

KZRKezar Life Sciences2019-11-08 21:13 EST

Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616

SLSSELLAS Life Sciences Group, Inc.2026-11-04 14:00 EST

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

ACHVAchieve Life Sciences2026-03-26 12:30 EST

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

RGENRepligen2025-11-04 12:30 EST

Repligen Corporation to Present at Upcoming November Conferences

ACHVAchieve Life Sciences2026-11-02 13:30 EST

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

View all latest news

Wave Life Sciences

RNA Medicines Platform Company Wave Life Sciences is a clinical-stage biotechnology company developing RNA medicines across both rare and common diseases. Its PRISM platform combines RNA-targeting modalities, chemistry innovation, and human genetics to design medicines that can address disease biology through RNAi and RNA...